Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06597799 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of MRT-6160 in Healthy Subjects
A Phase 1 study, sponsored by Monte Rosa Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
NCT06597799 is a Phase 1 study that has completed, run by Monte Rosa Therapeutics. The registered enrollment target is 108 participants.
The verdict
NCT06597799, a Phase 1 study, has completed, sponsored by Monte Rosa Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
Study Summary
The principal aim of this study is to obtain safety and tolerability data when MRT-6160 is administered orally as single and multiple doses to healthy subjects. This information, together with the pharmacokinetic (PK) data, will help establish the doses and dosing regimen suitable for future studies in patients. The study drug, MRT-6160, is experimental. This is the first study in which MRT-6160 will be given to humans. Part 1: Subjects will receive a single oral dose of MRT-6160 or placebo on Day 1 Part 2: Subjects will receive multiple oral doses of MRT-6160 or placebo for 7 consecutive days
Interventions
- DRUG Placebo
- DRUG MRT-6160
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2024-08-07 |
| Est. Completion | 2025-04-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06597799
The ClinicalTrials.gov registry entry for NCT06597799 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Monte Rosa Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06597799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06597799 about?
NCT06597799 is a clinical study titled "First-in-human Study of MRT-6160 in Healthy Subjects". The principal aim of this study is to obtain safety and tolerability data when MRT-6160 is administered orally as single and multiple doses to healthy subjects. This information, together with the pharmacokinetic (PK) data, will help establish the doses and dosing regimen suitable for future studies...
What is the current status of trial NCT06597799?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2024-08-07. Estimated completion is 2025-04-10.
What interventions are being tested in trial NCT06597799?
The interventions under investigation include: Placebo (DRUG), MRT-6160 (DRUG).
Who is sponsoring clinical trial NCT06597799?
This trial is sponsored by Monte Rosa Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.